Search Videos and More
News
Taming Chronic Inflammation
Dana-Farber researchers explore how lifestyle choices may help reduce cancer risk and improve outcomes
News
Dana-Farber Research News 02.01.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from December 16 - 31.
News
Addition of CDK 4/6 inhibitor benefits patients with HR+, HER2+ metastatic breast cancer, new study shows
The addition of a CDK 4/6 inhibitor to standard therapy in patients with “double-positive” metastatic breast cancer significantly extended the time the disease did not progress according to data published today in the New England Journal of Medicine.
News
Ten Cancer-Related Breakthroughs Giving Us Hope in 2026
Cancer treatment has evolved dramatically in the first quarter of this century, but there is still much more to do to improve the lives of people with cancer.
News
More Than 145 Dana-Farber Affiliated Faculty Named as 2026 Top Doctors™ in Boston Magazine
Boston magazine has named more than 145 physicians affiliated with Dana-Farber Cancer Institute to its annual "Top Doctors" guide. Drawing from a Castle Connolly Medical Ltd. physician database, the Boston magazine Top Doctors™ list draws from hundreds of Boston-area physicians in many medical specialties
News
ADC Combination Outperforms Standard Treatment of Advanced Triple-Negative Breast Cancer
In patients with advanced triple negative breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus pembrolizumab led to durable responses and improved progression free survival compared to the current standard treatment, according to results of the ASCENT-04/KEYNOTE-D19 study, published today in the New England Journal of Medicine.
News
Dana-Farber Researchers Create Experimental AI-based Oncologist’s Assistant
There are over 100 precision medicines approved for the treatment of cancer. These therapies work to shut down the cancer-driving effects of specific mutations.
Document
Tip Sheet: Laboratory Monitoring for Patients on Oral Chemotherapy or Oral Targeted Therapies
The Breast Oncology Center developed this reference for providers on lab monitoring for patients on oral chemotherapy or oral targeted therapies in November 2025.
Course
3rd Annual Lynch Syndrome Scientific Symposium
The 3rd Annual Lynch Syndrome Scientific Symposium will be held on Monday, April 13 at Hotel Commonwealth in Boston, MA. This symposium is dedicated to researchers and clinicians focused on the study and clinical care of individuals with Lynch syndrome. We will be accepting abstracts on Lynch syndrome research and relevant case reports. The deadline to submit an abstract is February 16, 2026 at 11:59PM EST.
News
Dana-Farber Research News 01.15.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from December 16 - 31.
Symposium
Breast Cancer Breakthroughs: ESMO 2025 Highlights
Experts in Dana-Farber’s Breast Oncology Center discuss highlights in breast cancer research innovation presented at ESMO25 in Berlin, Germany, including what the data means, how it can be used in clinic, and what’s next in the field of breast cancer research.
News
Dr. Mariella Filbin Receives 2026 Emerging Leader Award from The Mark Foundation
he Mark Foundation for Cancer Research has named Dr. Mariella Filbin, Research Co-Director of the Pediatric Neuro-Oncology Program at Dana-Farber Cancer Institute, the recipient of the 2026 Emerging Leader Award, recognizing her innovative work to advance treatment options for aggressive childhood brain tumors.